Psoriasis affects 7.55 million US adults, yet only one in five carries the moderate-to-severe disease that reaches biologics.

Psoriasis prevalence among US adults is 3.0%, or an estimated 7.55 million adults, and has been stable since 2003 per NHANES data from 2011 to 2014 (Armstrong et al., PMID 34190957). Prevalence is not uniform: it runs highest in White adults at 3.6% and lowest in Black adults at 1.5%, a gradient that shapes diagnosis rates and access. Plaque psoriasis is the dominant morphology, and disease severity, not headcount, governs where systemic and biologic therapy is actually used across the population.

Two clinical facts drive commercial concentration. First, only a minority of patients, roughly one in five per National Psoriasis Foundation estimates, carry moderate-to-severe disease qualifying for systemic therapy, defined in trials as PASI of 12 or above, body surface area of 10% or more, or IGA of 3 or above. Second, psoriatic arthritis co-occurs in 19.7% of psoriasis patients (North America 19.5%, Alinaghi et al., PMID 29928910), pulling a large subgroup toward mechanisms with joint efficacy and rheumatology co-management. Standard care escalates from topicals and phototherapy through conventional systemics to biologics and oral TYK2 therapy.

Severity, not prevalence, decides who reaches biologic therapy.

Five questions this report answers:

Q1 - Of 7.55 million affected adults, how many are genuinely biologic-eligible and treated today?

Q2 - How does the 19.7% psoriatic arthritis overlap redirect mechanism choice and specialty ownership?

Q3 - What does the White-to-Black prevalence gradient imply for underdiagnosis and access equity?

Q4 - How common is plaque psoriasis in the US, and which patients reach systemic therapy?

Q5 - What clinical thresholds (PASI, BSA, IGA) define moderate-to-severe psoriasis eligible for systemic therapy?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Psoriasis #Biologics #Dermatology #PsoriaticArthritis #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/psoriasis/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/